Can-Fite BioPharma Ltd. CANF 深 滬
等待開盤 08-05 09:30:00 美东时间
0.6745
+0.018
+2.74%
華盛通- 最 高0.6863
- 今 開0.67
- 成交量 8.47万股
- 最 低 0.67
- 昨 收 0.6565
- 總市值 868.57万
- 52周最高 3.12
- 市盈率 靜 --
- 換手率 0.66%
- 52周最低 0.632
- 委 比 -66.67%
- 總股本 1287.72万
- 歷史最高 1419.00
- 量 比 0.09
- 振 幅 2.48%
- 歷史最低 0.632
- 每 手 1
- 風險率 0.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Can-Fite BioPharma Achieves Enrollment Milestone in Pancreatic Cancer Trial
Can-Fite BioPharma ( ($CANF) ) has shared an announcement. On July 30, 2025, Ca...
07-30 19:27
Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone
Can-Fite BioPharma Ltd. announced over 50% enrollment in Namodenoson's Phase 2a pancreatic cancer trial, highlighting its favorable safety profile and anti-tumor activity. Namodenoson, an A3AR agonist, is being evaluated for safety, clinical activity, and pharmacokinetics in advanced pancreatic adenocarcinoma patients. The study is led by Prof. Salomon Stemmer and reflects strong interest in exploring Namodenoson as a potential treatment for panc...
07-30 11:04
Can-Fite Prices $5M Public Offering Of 8.33M ADSs At $0.60/ADS, Plus Warrants To Purchase 16.67M ADSs For Up To $10M More
Can-Fite BioPharma Ltd.
07-29 00:28
Can-Fite's Piclidenoson Shows Effect in UCLA Study on Vascular Dementia, a Disease With No Approved Treatments
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced
07-28 19:08
Can-Fite Announces Up To $15.0 Million Public Offering
Can-Fite BioPharma Ltd. announced the pricing of a public offering raising $5 million upfront, with potential additional $10 million from short-term warrants. The offering involves 8.333 million ADSs and warrants for 16.666 million ADSs, priced at $0.60 each. Warrants are exercisable immediately with a 24-month expiry. Proceeds will fund R&D, clinical trials, and general corporate purposes. The company's lead drug, Piclidenoson, has Phase 3 resul...
07-28 16:24
Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia
Can-Fite BioPharma Ltd. announced that Piclidenoson, its A3 adenosine receptor agonist, demonstrated efficacy in a vascular dementia mouse model, restoring tissue integrity and behavioral function. Vascular dementia, the second most common cause of dementia, lacks FDA-approved therapies, with current treatments offering limited benefit. Piclidenoson's potential as a disease-modifying agent could address this unmet need and capture a significant s...
07-28 11:00
Can-Fite BioPharma launches best-efforts offering of ADSs and warrants
Can-Fite BioPharma (NYSE:CANF) is offering up to 4.9 million ADSs (representing 1.47 billion ordinary shares) and 4.9 million common warrants in a best-efforts offering. Each ADS will be sold with one...
07-24 05:41
Can-Fite BioPharma To Present Update On Ongoing Phase Iia Study In Pancreatic Cancer During Partnering Meetings At 2025 BIO International Convention
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced
06-16 21:01
Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston
Can-Fite BioPharma announced that Dr. Sari Fishman will present updates on its Phase IIa study of Namodenoson in pancreatic cancer at the 2025 BIO International Convention. The trial, led by Prof. Salomon Stemmer, evaluates the safety, efficacy, and pharmacokinetics of the drug in advanced pancreatic adenocarcinoma patients. Half of the planned patients have been enrolled, and Namodenoson has shown a favorable safety profile. Can-Fite aims to adv...
06-16 13:00
美股大行评级 | 潜在涨幅684.71%！Verve Therapeutics获Canaccord Genuity升目标价至39美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1119185980869894144.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Canaccord Genuity：维持Verve Therapeutics(VERV)"买入"评级，目标价从32美元升至39美元</p> <p>• HC Wainwright & Co.：维持Verve Ther
04-16 09:45
